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Abstract
Background: The HIV epidemic has challenged our previous understanding of endemic Burkitt's
lymphoma. Despite the strong association of Burkitt's lymphoma and HIV infection in the
Developed world, and against previous postulations that the cancer is due to immunosupression
among African children, the HIV epidemic in the Malaria belt has not been associated with a
corresponding increase in incidence of childhood Burkitt's lymphoma. Even outside the context of
HIV infection, there is substantial evidence for a strong but skewed immune response towards a
TH2 response in genesis of Burkitt lymphoma.
Presentation of the hypothesis: Rather than a global and/or profound immunosupression, the
final common pathway in genesis of Burkitt's lymphoma is the dysregulation of the immune
response towards a TH2 response dominated by B-lymphocytes, and the concomitant suppression
of the TH1 cell-mediated immune surveillance, driven by various viral/parasitic/bacterial infections.
Testing the hypothesis: Case control studies comparing TH2 and TH1 immune responses in
Burkitt lymphoma of different etiological types (sporadic, HIV-related, endemic and post-
transplant) to demonstrate significant dominance of TH2 immune response in presence of poor
CMI response as a common factor. Immunological profiling to evaluate differences between
immune states that are associated (such as recurrent Malaria infection) and those that are not
associated (such as severe protein-energy malnutrition) with Burkitt lymphoma. Prospective
cohorts profiling chronology of immunological events leading to Burkitt lymphoma in children with
EBV infection.
Implications of the hypothesis: The dysregulation of the immune response may be the missing
link in our understanding of Burkitt lymphomagenesis. This will provide possibilities for
determination of risk and for control of development of malignancy in individuals/populations
exposed to the relevant infections.
Background
Burkitt lymphoma represents the first strong association
of cancer and viral infection – Epstein – Barr virus [1]. The
striking endemicity, different epidemiological forms, fast
progression and peculiar dramatic clinical presentation of
Burkitt lymphoma still make it an invaluable tumor for
studying oncogenesis [2,3]. Yet less than enough effort
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has been put in elucidating the immunological and
cytogenetic mechanisms of genesis of this tumor.
The exact contribution of EBV to BL genesis remains con-
troversial. There is evidence that EBV infection causes
excessive B-cell proliferation by chronic stimulation of
immunoglobulin genes [4]. The mode of stimulation has
been suggested to be by causing expression of somatic
hypermutation inducing molecules – including activa-
tion-induced cytidine and polymerase-eta [5]. Ultimately
accrual of oncogenic mutations occurs. Whether and how
EBV contributes to cytogenetic lesions including c-myc
reciprocal translocations, bcl-6 mutations and the univer-
sal p53 mutation is not certain [6]. It is suggested that
these cytogenetic lesions may be constitutive, as a result of
B-cell hyperproliferation. Though EBV does immortalize
B-cells in vitro to form lymphoblastoid cell lines, these
LCLs are phenotypically distinct from Burkitt's tumor cells
[7,8] – suggesting other in vivo factors play part in
Burkitt's malignant transformation. The phenotype of the
EBV-transformed B-lymphocytes suggests that the effect of
viral protein expression mimics that of antigen-driven
lymphocyte activation [9]. It is also worth noting that EBV
infection is not a necessity to genesis of BL, though
present in a vast majority of cases.
Malaria and malnutrition, both very common in Equato-
rial Africa, are thought to play part in the immunological
events leading to lymphomagenesis [10-12]. Specifically,
Malaria is known to alter cytokine production resulting in
polyclonal B cell activation and impairment of EBV-spe-
cific T cell responses [13,14]. Recent evidence also sug-
gests that Malaria facilitates EBV replication [15].
However, neither Plasmodium falciparum  nor Epstein-
Barr virus infection has been associated with increased
detection of chromosomal translocations [15,16].
With that background understanding of the genesis of
Burkitt lymphoma and the nature of interaction of tumor,
Epstein – Barr Virus and Malaria, it would be logical that
a "Burkitt tumor epidemic" follows the HIV/AIDS epi-
demic in Africa. HIV infection would be expected to act as
catalyst to Burkitt lymphomagenesis. In fact the incidence
of Burkitt Lymphoma in Europe/North America has expo-
nentially risen since the advent of HIV [18-20]. However,
even in the Western setting, BL has been demonstrated to
occur in the early stages of HIV infection when immuno-
supression is mild or even absent [21-24].
Even before the HIV/AIDS era there were observations
suggesting selective suppression and enhancement of dif-
ferent aspects of the immune response in patients with
Burkitt Lymphoma. Though there are no studies directly
correlating this, anecdote indicates that the tumor is not a
feature of severely malnourished (e.g. those with Kwash-
iorkor/Marasmus) African children. In the context of HIV-
infection, B-cell stimulation (indicated by higher serum
globulin) is an independent predictor of NHLs and precedes
the diagnosis of NHL by several years [22]. Severe post-
chemotherapy immunosupression is also not associated
with neo- or relapse of Burkitt's tumor [25]. Though of B-
cell origin, post-transplant lymphoproliferative disorders
are also predominantly of non-Burkitt phenotype usually
diffuse large B-cell lymphomas [26,27].
HIV infection and Burkitt lymphoma in Africa
Human Immunodeficiency virus is the most effective bio-
logical immunosupressant known to man. As such, it has
resulted in a cancer epidemic – in Africa – and worldwide.
HIV infection has been confirmed to favor production of
cytokines IL-4 and IL-10 resulting in a TH2 dominant
immune profile, which enhances B-cell proliferation
[28,29].
HIV/AIDS-associated haematological malignancies tend
to be particularly of B-cell origin; have a tendency to
present in extra nodal sites, rapid clinical progression, and
are associated with Epstein-Barr virus (EBV) infection
[18]. Burkitt lymphoma therefore has all features typical
of HIV-associated lymphomas. Paradoxically, since the
advent of the HIV epidemic almost all studies in Sub-
Saharan Africa have consistently demonstrated no
increased incidence of BL in general, nor among children
with HIV infection specifically.
Chifumbe Chintu et al, 1995 in Zambia, compared his-
topathological records 1980 – 1982 vs. 1990 – 1992, at
University Teaching Hospital, Lusaka [30]. They demon-
strated that the [reported] incident cases of Burkitt lym-
phoma significantly reduced: 18 vs. 11 (p = 0.05) in the
HIV/AIDS era. Other clinical and demographic character-
istics of Burkitt lymphoma remained unchanged.
A case series in Zimbabwe in 1998 studied 76 consecutive
cases of all newly diagnosed childhood cancer over a 6-
month period at The Paediatric Oncology Unit, Parireny-
atwa Teaching Hospital [31]. Despite a very high HIV
seroprevalence rate in the study group – 27 out of 64 chil-
dren assessable for HIV serology were HIV positive, a sero-
prevalence of 42.2% – no cases of Burkitt lymphoma were
seen in all the 76 cases; most of them were Kaposi's sar-
coma and other Non-Hodgkin's lymphomas, mainly
Large cell.
The only study that suggested increased incidence of BL in
HIV-infected children was a case-control study investigat-
ing HIV infection & Cancer in Kampala Uganda 1998
[32]. The study showed a 5-fold increase of Burkitt lym-
phoma in HIV – infected children. 30% (10/33) HIV cases
vs. 6% (11/190) controls. (OR = 7.5, 95% CI 2.8 – 20.1,Infectious Agents and Cancer 2007, 2:10 http://www.infectagentscancer.com/content/2/1/10
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based on 33 cases of Burkitt lymphoma; p = 0.0001.)
However, this study noted the high likelihood of misdiag-
nosis [on light microscopy] of other types of Non-Hodg-
kin's lymphoma common in HIV infection as Burkitt
lymphoma. Other studies including by Mbidde et al. in
Uganda, Lazzi et al. in Kenya, Sinfield et al. in Malawi and
Lucas et al. in Côte d'Ivoire [33-36] did not find a positive
correlation between Burkitt lymphoma and childhood
HIV infection.
Perhaps the most robust study that has investigated this
issue was a case-control study done in Kampala Uganda in
1999, investigating Non-Hodgkin's lymphomas and HIV
infection with age/sex matched controls, and their rela-
tionship with EBV infection [37]. 132 children with a
mean age of 7 years were histologically diagnosed with
Burkitt lymphoma; of which 61 had tissues validated and
phenotyped confirming 56 as BL. HIV prevalence was
5.4% (3/54) in cases, compared with 5.0% (11/194) in
controls, corresponding to an OR of 1.0 (0.3–3.9). All
(51/51) cases of BL were EBV positive.
Therefore, evidence so far has demonstrated no positive
association of the HIV epidemic and incidence of Burkitt
lymphoma in sub-Saharan Africa. Why are African chil-
dren with HIV infection NOT prone to Burkitt tumour? A
simplistic explanation has been that the survival of Afri-
can children with HIV infection is so poor that they do not
leave long enough to have [clinical] Burkitt lymphoma
[37]. This however is questionable. If immunosupression
were the key major event leading to BL genesis, and know-
ing that EBV infection occurs early in childhood, and that
EBV and HIV enhance each other, why doesn't HIV infec-
tion hasten development of BL? Why do the children
instead suffer primary CNS and Non-Burkitt Non-Hodg-
kin lymphomas? I propose an alternative hypothesis tak-
ing all the above observations into account.
Presentation of the hypothesis
Considering the above epidemiological observations and
the current evidence regarding the cytogenetic events fol-
lowing chronic EBV infection, immune-dysregulation
seems to be the key/ultimate factor in causation of BL: A
prolonged hyperproliferation of B-cells (which predis-
poses them to cytogenetic lesions) stimulated by EBV; in
an individual with dominance of TH2 immune response
cytokines; and the subsequent and/or concurrent suppres-
sion of the TH1 immune response resulting in inefficient
tumour cellular surveillance, is the cause of Burkitt lym-
phoma. A global (Humoral and Cell-mediated) immuno-
supression or a depressed TH2 and TH1 immune profile,
may be "protective" against development of Burkitt lym-
phoma.
The hypothesis is consistent with the concept that onco-
genic cellular lesions that result in cancers may be a con-
sequence of an adaptive response to biologic stresses [38].
It highlights the polyclonal hyperproliferation of B-cells
that precedes genetic mutations leading to monoclonal
proliferation in BL; the permissive role of T-cell surveil-
lance failure; the over-determination and the multifacto-
rial infectious aetiology of BL [16]. It emphasizes that a
TH2-dominant immune profile serves a duo purpose of
propagating B-cell proliferation and suppressing T-cell
function at the same time. The hypothesis also explains
how EBV, HIV, Malaria and other Tropical infections act
synergistically in genesis of BL. Figure 1 below summa-
rizes the role of these infections.
A schematic summary of the TH1/TH2 immunodysregulation hypothesis of Burkitt lymphomagenesis Figure 1
A schematic summary of the TH1/TH2 immunodysregulation hypothesis of Burkitt lymphomagenesis.Infectious Agents and Cancer 2007, 2:10 http://www.infectagentscancer.com/content/2/1/10
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The above hypothesis is consistent with the observation
that Burkitt lymphoma is less common in individuals
with profound and/or global suppression of both B-cell
and T-cell mediated immune responses including child-
hood HIV/AIDS in the African setting, adults with
advanced HIV/AIDS in the Western setting and in post-
transplant lymphoproliferative disorders [22,26,37,39].
Children with severe protein-energy malnutrition seem to
be protected from Burkitt lymphoma. Profound nutri-
tional deficits (less than 5% protein per total daily food
intake) depress both cellular and humoral immunity [40].
Other studies on the modulation of the immune response
by moderate to severe chronic malnutrition have demon-
strated a suppression of B-cell immunity, and enhance-
ment of several aspects of T-cell immunity [41]. Several
animal laboratory studies have also confirmed this pat-
tern [42,43] – which (according to the hypothesis) is the
reverse of the recipe required for Burkitt lymphomagene-
sis.
The following study designs will test the hypothesis
▪ Case control studies examining blood samples of BL
patients of various aetiological types (endemic, Sporadic,
HIV-related and post-transplant) to demonstrate a domi-
nant TH2 immune response in presence of poor CMI
response as a common final pathway.
▪ Matched Case Control studies particularly profiling
TH1/TH2 immune responses in immune states associated
with BL (such as recurrent Malaria and early HIV infec-
tion) compared with immune states that are not associ-
ated with BL (such as severe Protein-Energy Malnutrition
and late HIV infection).
▪ Prospective cohorts evaluating the role of TH1/TH2
immune profiles in modification of risk of BL among chil-
dren with HIV/AIDS on HAART, in children with and who
survive severe Protein-Energy malnutrition, and in areas
of changing Malaria and other tropical infection endemic-
ity.
Implications of the hypothesis
Very few cases of oncogenic infections ever progress to
malignancy. If dysregulation of the immune profile is the
main event that leads to BL (or even other infectious can-
cers), determining the exposed individuals' immune pro-
files can be used to predict their likelihood of developing
malignancy before they manifest clinical disease.
If the endpoint in BL genesis is TH2/TH1 immune-dysreg-
ulation, several infectious/environmental factors (other
than EBV, Malaria, HIV) that contribute to lymphomagen-
esis, both in endemic and sporadic cases, may be identi-
fied and mitigated to modify the risk for malignancy.
The proposition that a B-cell malignancy such as BL may
result from "disorganization" of the immune response
challenges us to formulate immunotherapeutic strategies
that will selectively target endogenous immunomodula-
tors especially in preventing disease relapse.
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